This activity is supported by educational grants from Bristol Myers Squibb; Genentech, a member of the Roche Group; Merck Sharp & Dohme Corp.; and Regeneron Pharmaceuticals, Inc and Sanofi.
Oncology NPs, PAs, and nurses
Upon completion of this activity, participants should be able to:
Identify currently approved ICIs and the role of biomarker testing in their use in advanced NSCLC
Describe recommended, evidence-based strategies to individualize treatment with ICIs for patients with advanced NSCLC
Implement effective strategies for identification and management of irAEs in patients treated with ICIs
Sandip P. Patel, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, and Rakuten Medical; researcher: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Iovance Biotherapeutics, Merck, Pfizer.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
This program has been made available online.